Article
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.
ESMO open - 1 Dec 2021
Tabernero J, Velez L, Trevino T L, Grothey A, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, Yoshino T, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S
Abstract excerpt
Colorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with metastatic colorectal cancer (mCRC). Patients with BRAF V600E mutations, which occur in ∼10%-15% of patients with mCRC, have a poorer prognosis compared with those with wild-type BRAF tumours. The combination of the BRAF inhibitor encorafenib with the epidermal growth factor receptor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.